COVID-19 infection and vaccination in patients with inflammatory bowel disease (IBD)
Project leader: Dr. med. Henrike Lenzen
Key area
- Pathophysiology: immunmodulation and immune control
Who is involved?
- Dr. med. Henrike Lenzen (Project leader, MHH)
- Dr. med. Miriam Wiestler (MHH)
- Prof. Dr. Yang Li (CiiM, HZI)
What is the aim?
This is a prospective observational study to evaluate the course of COVID-19 disease in patients with inflammatory bowel disease (IBD) and to evaluate the response to COVID-19 vaccination in this specific immunocompromised group of patients. The quality and duration of the antibody and T-cell responses before and after vaccination will be characterised in more detail, and the response to vaccination and the course of the underlying IBD in the included IBD patients will be investigated and compared.